CUTE PROMYELOCYTIC leukemia (APL) is associ-
0, and y ) are activated by 9-cis-RA ~n l y . '~-'~ Several groups have shown that RARs must heterodimerize with RXRs for effective DNA binding and transactivation,17.18 and that RXRs can form homodimers and activate specific response elements that are different to those activated by RAR-RXR heterodimers. 1920 It has been recently shown that in myeloid leukemic cells not carrying the PML-RARa chimeric receptor, the differentiating and antiproliferative effects of retinoids are mainly induced by a pathway involving RAR/RXR heterodimers." mRNA expression in a manner similar t o NB4 cells. The molecular mechanisms involved in the induction of these genes were investigated. In NB4 cells, using novel receptor-selective ligands such as 9-cis-RA, TTNPB, AM580, and SR11217, we found that RAR-and RARa-selective retinoids were able t o induce growth arrest, granulocytic differentiation, and type II TGase, whereas the RXR-selective retinoid SR11217 was inactive. Moreover, an RARa-antagonist completely inhibited the expression of type II TGase and CD18 induced by these selective retinoids in NB4 cells. In NB4.306 cells, an RARa-dependent signaling pathway was found involved in the modulation of CD18 expression. In addition, expression of the PML-RARa gene in myeloid U937 precursor cells resulted in the a b i l i of these cells t o induce type II TGase in response t o t-RA. On the basis of these results we hypothesize a specific involvement of a signaling pathway involving PML-RARa for the induction of growth arrest, granulocytic differentiation, and type II TGase by retinoids in APL cells. However, in APL the precise molecular mechanism of RAinduced differentiation of promyelocytes has yet to be elucidated. Different groups have demonstrated that PML-RARa fusion protein binds all-truns-RA,22 dimerizes with PML, RARa, and RXR in vitro as well as in v~v o ,~~-~' and exhibits altered transactivating properties compared with RARcI.'.~
In a variety of cell systems, retinoids regulate the expression of transglutaminases (TGases), a group of Caz+-dependent enzymes that catalyze the formation of y-glutamyl-€-lysine cross-links between proteins.26 Several distinct transglutaminase genes have been identified and character-ized, including those encoding blood coagulation factor XIII, the membrane bound, type I (epidermal) TGase, and the cytosolic, type I1 (tissue) T G~s~. " -'~ A role in regulating cell growth, morphology, adhesion, and apoptosis has been suggested for type I1
In myeloid cells, type I1
TGase may play a role in regulating cell growth and different i a t i~n .~~. '~ Recently, type I1 TGase has been found to be involved in signal transd~ction~~ and cytokine a~tivation. '~ In this study, we analyze the expression of TGases during RA-induced differentiation in the APL-derived NB4 cell line and in the t-RA-resistant NB4.306 clone. The retinoid signaling pathways involved in these effects were delineated using retinoid-receptor selective ligands, an antagonist, and myeloid precursor U937 cells expressing the transfected PML-RARa gene product. Type I1 TGase expression was also investigated in fresh, patient-derived APL leukemic cells. Our results suggest that induction of type I1 TGase in APL cells is specifically related to retinoid responsiveness and is directly mediated through a retinoid signaling pathway that involves PML-RARa.
MATERIALS AND METHODS
The human myeloid leukemia cell lines used in this study were the following: the acute promyelocytic leukemia NB4 cell line, obtained from Dr M. Lanotte (INSERM, Paris, France), that contains the t(15;17) and expresses both RARa and PML-RARa p r~t e i n~~. '~; the RA-resistant NB4.306 cell line derived from NB4 cells, expressing an altered PML-RARa product3*; and the wildtypc promonocytic cell line U937 and the U937 MTPR clone, which contains the PML-RARa coding sequence under the control of the Zn2'-inducible mouse MT-I p r~m o t e r .~ All of these cell lines were maintained in RPMI 1640 medium supplemented with 50 IU/mL of penicillin, 50 pg/mL streptomycin, and 10% fetal calf serum (FCS).
Peripheral blood (PB) was obtained from informed, newly diagnosed APL patients classified as M3 or M3-variant by morphologic criteria according to the French-American-British (FAB) classification3' and presenting an initial percentage of circulating blasts that was more than 80%. Analysis of the PML-RARa fusion gene was performed as previously described." Leukemic cells were isolated and enriched on Ficoll-Hypaque density gradients (Pharmacia, Uppsala, Sweden), and washed twice with calcium-magnesium free phosphate-buffered saline (PBS). Cell pellets were stored at -80°C to be assayed for transglutaminase activity or resuspended in RPMI 1640 medium containing 20% FCS and plated for 1 hour at 37°C. Unattached cells were then plated in T12.5 flasks at a density of 3 X 10' cells/mL in 2 mL of the above-specified media and treated with t-RA at 37°C in a humidified atmosphere containing 5% COz. Experiments were performed using duplicate flasks per experimental point.
t-RA, 9-cis-RA, the RAR selective retinoid TTNPB (Ro 1 3-7410),4' the RARa-selective retinoid AM580 (Ro 40-6055),42 the RARy selective Ro 47-2077 (also known as CD43742), the RXR selective retinoid SRI-I 1217,19 and the RARa-antagonist Ro41-525343 were synthesized by the Department of Medicinal Chemistry (Hoffmann La Roche, Nutley, NJ). N-(4-Hydroxyphenyl)retinamide (HPR) is a synthetic retinoid effective in inducing apoptosis in a variety of myeloid cell linesM Cell proliferation was evaluated by direct cell counting (trypan blue dye exclusion method) using a hematocytometer chamber. Cell differentiation was quantified by the nitroblue tetrazolium (NBT) dye reduction assay:' and the percentage of positive cells was enumerated (at least 200 cells per experimental condition) as previously described.& Cell culture.
Retinoids.
Cell proliferation and differentiation.
Analysis of t-RA-binding activity. For RA-specific binding assay, nuclear and cytosolic extracts were prepared, incubated for 18 hours at 4°C with 10 nmol/L ['HI-t-RA (50.7 Ci/mmol; DuPont-NEN, Boston, MA) and analyzed at 4°C by high-performance liquid chromatography as previously des~ribed.~'.~'.~' A Superose 6 HR IO/ 30 size exclusion column (Pharmacia), was used to obtain a better separation of large molecular weight (MW) proteins and protein complexes. Cytosolic extracts were loaded over a Superose 12 HR 10130 column that resolves small MW proteins such as cellular RA binding proteins (CRABPs). The flow rate was 0.4 mL/min when the Superose 6 column was used, and 0.5 mL/min for the Superose 12 column. Fractions were collected and radioactivity was determined using a scintillation counter. The elution times of a series of specific molecular weight markers were measured by AZXO and used to calibrate the size exclusion chromatography systems. These protein markers included the following: blue dextran, MW 2,000,000; thyroglobulin, MW 669,000; apoferritin, MW 443,000; alcohol dehydrogenase, MW 150,000; bovine albumin, MW 66,000; ovalbumin, MW 45,000; carbonic anydrase, MW 29,000; lysozyme, MW 14,300.
Total RNA was isolated from the cells by the guanidine thiocyanate-CsC1 procedure4* or using the Tri Reagent (Molecular Research Center, Inc., Cincinnati, OH), and the manufacturer's protocol. Equal amounts of total RNA (30 pg) were separated by electrophoresis in 0.66 mol/L formaldehyde-1.2% agarose slab gel, transferred to Nytran membrane (Schleicher and Schuell, Hayward, CA) by capillary blotting and cross-linked by UV i r r a d i a t i~n .~~ An RNA ladder (Bethesda Research Laboratories, Bethesda, MD) was used as RNA size standards. Probes were prepared using the random primers DNA labeling kit and a protocol from Stratagene (La Jolla, CA). The cDNA probes were labeled with [a-32P]deo~y~ytidine triphosphate (dCTP) (3,000 Ci/mmol; DuPont-NEN). Blots were prehybridized in 10 mL of QuickHyb reagent (Stratagene) at 68°C for 1 hour. Hybridizations were performed for 2 to 4 hours at 68°C using the prehybridization buffer described above with [32P]-labeled probes (2 X 10' cpm/mL). Blots were washed twice in 2X SSC (SSC = 0.15 mol/L NaCI/O.OIS mol/L sodium citrate, pH 7.0), 0.1 % sodium dodecyl sulfate (SDS) at room temperature, once in 0.2X SSC, 0.1% SDS for 20 to 30 minutes at 60°C. Autoradiography was performed with Kodak XAR-5 film (Eastman Kodak, Rochester, NY), at -70°C using two intensifying screens (Lightning Plus, DuPont, Wilmington, DE).
The type I1 transglutaminase probe was the 3,348-bp EcoRI restriction fragment of the recombinant cDNA clone pTG3400," kindly provided by Dr P. Davies (University of Texas, Houston).
The CD18 probe was a cDNA fragment of the common p subunit of the human leukocyte adhesion proteins49 (kindly provided by Dr T. A. Springer, Dana-Farber Cancer Institute, Boston, MA). The GAPDH was the 1,120-bp Pst I cDNA restriction fragment of the chicken glyceraldehyde-3-phosphate dehydrogenase plasmid pGAD-28," used to standardize the level of gene expression.
Cells (2 X 10' cells/mL) were cultured in suspension in T25 tissue culture flask in 5 mL of defined media. Cells (about 1 to 5 X IO6) were collected by centrifugation and washed twice in calcium-magnesium free PBS containing 1 mmol/ L EDTA and 1 mmoUL phenylmethylsulfonyl fluoride. Pellets were stored at -70°C until assay was performed. Cell pellets were resuspended in 200 pL of the same phosphate buffer solution and sonicated for 10 to 15 seconds at 4°C. After taking an aliquot for total protein determination, dithiothreitol was added to the remaining homogenate to a final concentration of IO mmollL. The homogenate was then centrifuged at 4°C for 5 minutes at 10,00Og, yielding the soluble and particulate fractions. Transglutaminase activity assays were performed as previously described, on total homogenate, particulate, and soluble fractions to determine, respectively, the total, type 
Imunoblor analysis.

RESULTS
Effect of t-RA on the proliferation, differentiation, and transglutaminase activity in NB4 and NB4.306 cells. We first investigated the changes in the transglutaminase activity, the rate of proliferation and status of differentiation in NB4 and NB4.306 cell lines cultured in the presence and absence of 1 pmoVL t-RA (Fig 1) . In NB4 cells, t-RA treatment caused growth arrest, sta.ting after 3 days of treatment ( Fig 1A) and differentiation, detectable as NBT positivity in about 50% of cells after 2 days of treatment ( Fig 1C) . Conversely, growth and differentiation were not or only slightly affected by t-RA in NB4.306 cells, a t-RA-resistant subclone of the NB4 cell line which lost the potential to encode for an intact, RA-binding PML-RARa fusion protein but expresses functional RARa product (Fig 1B and D) . Very low levels of transglutaminase activity were measurable in either the soluble and particulate fraction of both these cell lines, and no significant change of this enzyme activity was detected over the time in untreated cells. The transglutaminase activity associated with the soluble fraction, thus representing the type I1 TGase, was dramatically induced in response to 1 pmol/L t-RA in NB4 cells ( Fig  1E) . This t-RA-induction started after 8 hours of treatment and reached a maximum of about a 2,000-fold increase above baseline levels in 4 to 5 days. In NB4.306 cells, type I1 TGase activity was only increased 5-to 20-fold by t-RA. A low transglutaminase activity (<lo% of total) was found associated with the particulate fraction of these cell types treated or not with t-RA. A slight increase in TGase activity was measurable in the Particulate fraction of NB4 cells after t-RA treatment (data not shown). This increase was probably caused by a contamination of the particulate fraction with supernatant.
Induction of type I1 TGase and CDl8 mRNAs in NB4 and NB4.306 cells. The ability of these cells to differentiate and to increase type I1 TGase activity in response to t-RA was further investigated by measuring the induction of the leukocyte adherence p subunit (CD18) gene. CD18 gene is an RA-responsive differentiation-specific gene that is transcriptionally upregulated during the RA-induced morphologic differentiation in myeloid leukemia HL-60 cell line. 53 In NB4 cells, t-RA upregulated both the type I1 TGase 4.0-kb mRNA transcript and the CD18 3.0-kb mRNA transcript (Fig 2A) . In NB4.306 cells, type I1 TGase mRNA induction by t-RA was not detectable (Fig 2A) . However, t-RA was able to induce the expression of CD18 mRNA to a similar degree as in NB4 cells (Fig 2A) .
We next investigated whether the effect of t-RA on expression of these genes was direct or indirect through the induction of another gene product. NB4 cells were treated with cycloheximide (10 pg/mL) 30 minutes before the addition of t-RA (I pmol/L) and throughout the t-RA treatment ( Fig 2B) . Only a slight decrease in the expression of type I1 TGase and CD18 "As was seen in NB4 cells after 8 to 12 hours of treatment with both t-RA and cycloheximide, suggesting that protein synthesis is not necessary and that transcriptional upregulation of these genes may be directly mediated by t-RA (Fig 2B) .
HPLC analysis of t-RA-binding activity in NB4 and NB4.306 cells. It has been previously shown that the NB4 cell line, in addition to the PML-RARa and RARa transcripts, also expresses transcripts encoding for RXRa and RXRp23"4 (L. Benedetti and C. Nervi, unpublished results, May 1995). In these cells, t-RA or 9-cis-RA treatments were able to downregulate RXRa expression and to induce RAR p transcripts within 24 hours; however, RARy and RXRy transcripts were not detectable under similar conditions.
To identify the RA-induced signaling pathway involved in type I1 TGase and CD18 inductions, we first analyzed the t-RA-specific binding present in NB4 and in the RA-resistant cell line NB4.306. Analysis of specific t-RA binding activity was performed by size-exclusion high-performance liquid chromatography (HPLC) in nuclear extracts prepared use only. from NB4 and NB4.306 cells after incubation with ['HI-t-RA. In agreement with previous findings," three main peaks of specific t-RA binding activity were identified in NB4 cells. The specificity of the binding was indicated by the fact that 200-fold excess unlabeled t-RA inhibited the binding activities corresponding to molecular weights of approximately 670,000 to 460,000, I 10,000, and 50.000 (Fig 3A) . These peaks appear to correspond to the endogenous RARa (50,000). to the monomeric form of the PML-RARa product ( 1 10.000). and to the previously described high MW complexes probably formed by the interaction of PML-RARa with itself and/or with other nuclear
In contrast, the HPLC profile of nuclear extracts prepared from NB4.306 cells showed the presence of a single peak of specific t-RA binding eluting with an apparent MW of 50,000. RARs have been shown to possess molecular weights of 50,000, and RARa could be detected by Northern and immunoblot analysis in NB4.306 cells." Thus, this peak of t-RAspecific binding probably represents the endogenous RARa, whereas a specific t-RA binding corresponding to PMLRARa was absent in this RA-resistant APL cell line. None of the proteins described above could be detected in the cytosolic fractions (Fig 3B and D) . However, a small peak of specific t-RA binding eluting with an apparent MW of 18,000 consistent with CRABPs" was present in both NB4 and NB4.306 cells. Previous reports established a correlation between retinoid resistance and a point mutation in RARa in HL-60 cell?' or, in APL cells, an increased expression of CRABPs."" The resistance of NB4.306 appears to be different; in fact, these cells have functional binding and low levels of CRABP binding. These results suggest that multiple mechanisms may be responsible for the clinical resistance to RA that develops in post-RA therapy relapse in APL patients.","' Effect of receptor selective retinoid.y treatment in NB4 and NR4.306 cells. In NB4 cells, the RARa-selective retinoid AM580 and the RAR-selective retinoid TTNPB were the most effective in stimulating type 11 TGase activity and differentiation (measured as NBT reduction) after 48 hours of treatment (Fig 4 and data not shown) . The RXR-selective SRI 1217, a retinoid that selectively binds to RXRs and induces RXR-RXR homodimerization," failed to increase either type I1 TGase and CD18 mRNAs in NB4 cells (Fig 4) . Addition of 9-cis-RA, a retinoid that binds both RARs and RXRs with high affinity and is a very potent activator of either RAR-RXR heterodimers or RXR-RXR homodimers, I s. I h.2ll was just as effective as t-RA in causing a timeand dose-dependent increase in NB4 cell differentiation and in the expression of type I1 TGase and CDI 8 (Figs 4 and SA, and data not shown). The calculated for the induction of differentiation (measured as NBT reduction) and type I1 TGase activity were estimated to be approximately 40 nmol/ L for both t-RA and 9-cis-RA (data not shown). As expected, the RARy-selective retinoid Ro 47-2077 was unable to induce type I1 TGase (Fig 4) . In general. in NB4 cells the potency of the retinoids to induce NBT reduction correlated well with their ability to increase type I1 TGase (data not shown). These results indicated that binding and/or activation of RXRs by itself are not required for the regulation of differentiation, type I1 TGase, and CD18 expressions in NB4 cells. None of the retinoids tested were able to induce differentiation (not shown) or type I1 TGase &A expression in NB4.306 cells (Fig 5B) . In agreement with previous findings, a 6-to 16-fold increase in type I1 TGase activity was measurable in NB4.306 cells after 48 hours of treatment with t-RA and 9-cis-RA, respectively (Fig 4) . The RXR-selective retinoid SRI-11217 was not able to induce this enzyme in these cells. However, t-RA-and 9-cis-RA-induced CD18 mRNA expression was induced 7-to 10-fold over the steadystate levels within 24 hours of treatment (Fig 5B) . Although the levels of induction of CD18 were similar to those measured in NB4 cells 24 hours after treatment, after 72 hours the expression of this gene was still elevated in NB4 cells whereas the expression had decreased in NB4.306 cells. Thus, t-RA and 9-cis-RA treatments appear less effective in sustaining the expression of the CD18 gene at late times such as 72 hours in NB4.306 cells compared with NB4 cells. These findings indicate that in NB4.306 cells functional RAR-RXR heterodimers occur because CD 18 gene activation can be induced by retinoids. Moreover, in these cells CD18 expression i s not associated with granulocytic differentiation. At variance with NB4 cells, the RXR selective retinoid SR11217 (0.5 pmol/L) caused a sevenfold increase in CD18 mRNA expression after 24 hours of treatment in NB4.306 cells.
Correlation between type I1 TGase induction and apoptosis. A role for type I1 TGase in apoptosis has been suggested by several s t~d i e s~' *~~ and PML-RARa has been found to promote cell survival by inhibiting programmed cell death? The effect of N-(4-Hydroxyphenyl)retinamide (HPR), a synthetic retinoid which is able to suppress malignant cell growth by inducing apoptosis in a number of cells including NB4 and NB4.306 cell lines," was tested to investigate the correlation between type I1 TGase expression and use only. BENEDE7Tl ET AL induction of apoptosis. As shown in Figs 4, 5A, and 5B, treatment with 0.5 to 1 pmol/L HPR within 4 to 48 hours failed to induce type I1 TGase activity and mRNA expression in both NB4 and NB4.306 cells. CD18 expression was not affected by HPR treatment in these cell lines. In addition, by DNA fragmentation analysis and flow-cytofluorimetry we were not able to detect any increase in the apoptotic rate after 5 days of t-RA treatment (1 pnol/L) in both of these cell lines (data not shown). These results suggested that in APL cells type I1 TGase may play a role in differentiation rather than in apoptosis.
Effect of the RARa-selective antagonist Ro 41-5253 on type II TGase mRNA expression and activity. We next examined the effect of the RARa-selective antagonist Ro 41-5253, which has the ability to compete with retinoid-binding to RARCX;~ on the induction of type I1 TGase by RARaand RAR-selective retinoids. NB4 cells were treated for 48 hours with these receptor selective retinoids (1 nmol/L) in the absence or in the presence of increasing concentration of the RARa antagonist Ro 41-5253 (0.5 to 2 ymolk). Treatment of NB4 cells with the antagonist alone (2 pmoll L) had no effect on the level of type I1 TGase. As shown in Fig 6A and B, in NB4 cells the RARa antagonist was able to completely inhibit type I1 TGase expression and activity induced by 1 nmolk RARa selective retinoid AM580 as well as by 1 nmol/L RAR selective retinoid TTNPB. Similar results were observed hybridizing the same Northern blot with a CD18 cDNA probe (Fig 6A) .
Correlation between the expression of the PML-RARa protein in myeloid precursor cells and induction of type II TGase. To ascertain a direct role of the PML-RARa protein on these biologic events, we tested the induction of type I1 TGase by t-RA in the wild-type promonocytic leukemia cell line U937 which constitutively expresses RARa, and in the U937 MTPR clone expressing PML-RARa under the control of the Zn*+-inducible mouse MT-I promoter.' As previously des~ribed,~.'~ the RARa product could be detected by immunoblot analysis in these cells; 12 hours' treatment with 100 pmol/L Zn2' resulted in the induction of PMLRARa protein in MTPR cells (data not shown). Type I1 TGase protein was not detectable in cell extracts prepared from untreated cells or in cells induced only by Zn2' (Fig  7A) . Twenty-four hours of treatment with 1 pmol/L t-RA specifically induced type I1 TGase protein in samples prepared from Zn'+-treated MTPR U937 cells expressing the PML-RARa product. Enzymatic activity measurements indicated that this increase persisted during the entire 4-day period of t-RA treatment (Fig 7B) . These observations further support the role for t-RA binding to PML-RARa (but not to RARa) in the regulation of type I1 TGase expression in myeloid cells.
Type I1 TGase was also induced in a time-dependent manner by t-RA treatment in cultured cells from newly diagnosed APL Tvpe II TGase expression in fresh APL cells. Figure 8C shows type I1 TGase activity measured in vitro at time 0 and after 1 day of 1 pmol/L t-RA treatment in fresh APL cells from two patients, and in vivo (Fig 8B) on APL cells obtained from PB cells of APL patients expressing the PML-RARa gene on time 0 and on days I , 2, 3, 5, or 13 of combined all-trans-RA plus chemotherapy treatment." Also, in fresh APL leukemia cells, the levels of type I1 TGase appeared to be associated with t-RA-induced granulocytic differentiation, evaluated either morphologically (not shown) or as NBT reduction (Fig 8A) . In these cells, t-RA increased the level of type I1 TGase in a dose-dependent manner. The calculated ICso for this induction was 2.4 nmol/L, which was similar to that calculated for the induction of differentiation based on NBT reduction (data not shown).
The induction of this enzymatic activity by t-RA corresponded to increased levels of type I1 TGase protein ( Fig  9A) . Treatment with t-RA failed to induce differentiation or type I1 TGase activity (not shown) and protein in leukemic cells derived from two patients (P2 and P3, Fig 9B) initially defined as M3 by FAB criteria,3" but lacking the t(15;17).
DISCUSSION
In this study, we investigated the retinoid-induced signaling pathways that are involved in the regulation of type I1 TGase in APL cells. We provide evidence suggesting that in APL cells, the dramatic increase of type I1 TGase expression induced by retinoids is mediated through a PML-RARa signaling pathway and correlates with the ability of these cells to undergo growth arrest and differentiation. In addition, we found that in myeloid leukemia cells, an RARa-mediated signaling pathway is probably responsible for the CD18 induction by retinoids.
The induction of type I1 TGase by all-trans-retinoic acid has been implicated in growth regulation and/or differentiation in several cell lineages, including HL-60 cells.".")." The HL-60 myeloid leukemia cell line is morphologically and biochemically very similar to the APL blast but it lacks the t(15;17).' In this myeloid cell line t-RA increases type I1 TGase activity about 20-to 5O-f0ld.'~.'" Treatment of NB4 cells that express the PML-RARa product with t-RA caused an increase of about 1,000-to 2,000-fold in type 11 TGase activity. The induction of this enzymatic activity was related to an enhancement in the level of type I1 TGase protein (data not shown) and corresponding mRNA. Analysis of the time course and dose-responsiveness (data not shown) indicated that this induction correlated with the ability of these cells to growth arrest and to differentiate. Moreover, t-RA did not significantly alter the rate of growth arrest, differentiation, and type I1 TGase expression in NB4.306 cells, a t-RAresistant subclone of the NB4 cell However, in NB4 cells as well as in NB4.306 cells, treatment with t-RA was able to induce the leukocyte adherence subunit (CD18) expression. CD18 has been considered a marker for RAinduced differentiation in myeloid leukemia cells.'' Cycloheximide treatment did not block the t-RA induction of type I1 TGase and CD18 mRNAs, suggesting that the expression use only. , TGaseII a 50,000 MW, probably representing the endogenous RARa. Taken together, these results indicate that in NB4.306 cells a functional RARa receptor that may mediate the induction of CD18 mRNA expression by t-RA is present and that an alteration of the PML-RARa fusion product, and not RARa, is probably responsible for retinoic acid resistance in these cells.
For personal
Functional studies of the PML-RARa fusion protein'.' have shown that PML-RARa retains either the RARa DNA and retinoid binding domain and therefore can directly influence the RARa-dependent endogenous pathway that controls terminal myeloid differentiation. In addition, the fusion protein includes the C3HC4 zinc binding motif (RING finger), the BI and the B2 boxes of the PML protein that correspond to additional putative DNA-binding sequences. PML-RARa also forms heterodimers with RXR and PML as well as stable PML-RARa homodimers that can bind to directly repeated motif response elements with a different use only. In an attempt to analyze the signaling pathways induced by RA in APL cells. NB4 and NB4.306 cells were treated with novel receptor-selective retinoids. We found that in NB4 cells ( I ) RAR-and RARa-selective retinoids (TTNPB and AM580, respectively) were the most potent inducers of type I1 TGase, CD18, and differentiation; ( 2 ) treatment with 9-cis-RA that can activate RAR-RXR heterodimers, as well as RXR-RXR homodimers, was as effective as t-RA in inducing these effects; and (3) the RXR-selective retinoid SRI 1217 was unable to induce type I1 TGase, CD18, and differentiation. These findings indicate that the regulation of differentiation, and expression of type 11 TGase and CD18 are not mediated by RXR homodimers in NB4 cells. Conversely, in NB4.306 cells, only a slight increase in type 11 TGase activity of about 6-to 16-fold was measurable after treatment with t-RA and 9-cis-RA. This result was similar to the previously reported t-RA 20-to 50-fold induction of type I1 TGase activity in the myeloid cell line HL-60 which expresses RARm.'" In contrast to the results in HL-60 cells, none of these retinoids were able to induce differentiation in NB4.306 cells whereas treatment for 24 hours with either t-RA or 9-cis-RA was able to induce a 7-to IO-fold increase of CD18 mRNA expression. Therefore, it appears that in NB4.306 cells these retinoids acted through a wild-type RARm able to activate functional RAR-RXR heterodimers resulting in the induction of CD I8 mRNA. The genetic evidence of an involvement of RARm in this induction was further suggested by the fact that CD18 gene expression was In NB4.306 cells, the RXR selective retinoid SRI 1217 (0.5 pmol/L) was found able to increase (about sevenfold) CD18 mRNA expression after 24 hours of treatment. This result suggests that in these cells, RXR may directly mediate CDI 8 transcription through a complex with RXR or other nuclear transcriptional factors. The lack of CD18 mRNA induction in NB4 cells could be explained by sequestration of RXR into PML-RARa/RXR complexes. However, the increase in CD18 mRNA expression by SR11217 in NB4.306 cells could be also a consequence of the previously reported ability of this compound to slightly activate RAREs at similar concentration^.'^^^"
The RARa selective antagonist Ro 41-5253, which has the ability to specifically compete with RA for binding to RARa,4' completely antagonized the effect of RAR-and RARa-selective retinoids on type I1 TGase induction. As expected, this antagonist was also able to block the induction of CD18 mRNA expression by the RARa-selective retinoid AM580. Moreover, the RARa selective antagonist (2 pmoV L) was able to block type I1 TGase activity induced by 5 to 10 nmol/L of the less-specific retinoids t-RA and 9-cis-RA (data not shown). Although the experimental evidence obtained with these retinoids and with the antagonist does not rule out an involvement of RARa in type I1 TGase induction in NB4 cells, the dramatic increase in this enzyme expression measurable in t(l5; 17) positive myeloid cells again suggested a specific role for PML-RARa in this event.
In addition, a direct involvement of a PML-RARa-mediated signaling pathway in type I1 TGase induction was further supported by the introduction of PML-RARa in U937 cells. In fact, in myeloid precursor U937 cells that constitutively express RARa, treatment with t-RA failed to induce this enzyme expression. Type I1 TGase expression was strongly induced by t-RA in the same cells when expressing the transfected PML-RARa gene product. Moreover, the expression of PML-RARa in myeloid cell lines has been found related to the increased sensitivity of these cells to RA-induced differentiation. ' In agreement with these findings, a t-RA induction of differentiation and type I1 TGase expression were measurable in fresh cells from APL patients in culture as well as in cells directly taken from patients receiving t-RA plus chemotherapy treatment. None of these effects were determined in blast samples from t( 15; 17)-negative patients analyzed in similar experimental conditions. Type I1 TGase increase by t-RA has been recently shown in HL-60 apoptotic cells after treatment with t-RA.63 However, it has been shown that PML-RARa promotes cell survival by inhibiting programmed cell death.' In NB4 and NB4.306 cells, we could not find any correlation between type I1 TGase expression and apoptosis. Moreover, treatment with HPR, a synthetic retinoid that has little differentiating activity but is a strong inducer of apoptosis in a number of myeloid cell lines including NB4, NB4.306, and HL-60 cell^,"^ failed to induce the expression of either type I1 TGase or CD18. In agreement with these data, recent results obtained in bcl2-transduced HL-60 cells indicated that in myeloid cells distinct and separate molecular events are involved in the RA-induced granulocytic differentiation and apoptosis."."
These results indicate that in APL cells, the activation of PML-RARa signaling pathway by retinoids is important in initiating the molecular events that result in growth arrest and granulocytic differentiation. Type I1 TGase induction seems to be specifically involved in this PML-RARa -dependent pathway. Type I1 TGase then appears to be an early and specific marker of PML-RARa-mediated events that can be very useful in the assay of specific retinoids and provide future important therapeutical applications.
